Scholarlink

Background <p>Opioid analgesics are commonly used for controlling pain after total knee or hip replacement. However, it is unclear how much opioid should be prescribed at discharge after total hip and knee replacement surgery to optimize pain management but minimise adverse events. To determine the acceptability and feasibility of a trial comparing a reduced and standard opioid regimen following discharge from total knee or hip replacement.</p> Methods <p>This pilot randomized controlled trial recruited participants from the pre-admission clinic of a metropolitan hospital in Sydney. All participants received a non-opioid regimen of naproxen 500&#xa0;mg 12 hourly for 7 days, and paracetamol 1000&#xa0;mg 6 hourly daily for 14 days. Participants were randomly allocated to the ‘standard’ group (oxycodone 5&#xa0;mg taken as needed, maximum recommended frequency of 4 hourly, 20 tablets dispensed) or the ‘reduced’ group (received half the amount of oxycodone, taken half as frequently) at hospital discharge. Primary outcomes were screening to recruitment rate, percentage completing follow-ups, and acceptability of the trial procedures. Acceptability was measured quantitatively at weeks 1 and 2 post-discharge and qualitatively by interview at 6 weeks post-discharge. Adverse events were collected up to 6-weeks post-discharge.</p> Results <p>In four months, we screened 254 people, of which 72 were eligible and 53 were recruited (recruitment rate = 21%). 93% participants completed all their follow up surveys. Participants scored the trial intervention between neutral and acceptable (3.6/5 for both groups and weeks). 39 interviews were conducted where both clinicians and patients reported strong support for the pilot trial design. Few adverse events occurred across both groups, the most common being constipation.</p> Conclusions <p>This pilot trial indicated that a full-scale trial would be feasible and acceptable. Such a trial could provide evidence of comparative effectiveness for the reduced opioid regimen in this population.</p> Trial registration <p>The trial was pre-registered in Australian New Zealand Clinical Trials Registry (ACTRN12623001070628).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Reduced opioids after total joint replacement surgery (REPAIRS): a pilot randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月20日

查看全文
  • Zhiwei Yang

摘要

Background

Opioid analgesics are commonly used for controlling pain after total knee or hip replacement. However, it is unclear how much opioid should be prescribed at discharge after total hip and knee replacement surgery to optimize pain management but minimise adverse events. To determine the acceptability and feasibility of a trial comparing a reduced and standard opioid regimen following discharge from total knee or hip replacement.

Methods

This pilot randomized controlled trial recruited participants from the pre-admission clinic of a metropolitan hospital in Sydney. All participants received a non-opioid regimen of naproxen 500 mg 12 hourly for 7 days, and paracetamol 1000 mg 6 hourly daily for 14 days. Participants were randomly allocated to the ‘standard’ group (oxycodone 5 mg taken as needed, maximum recommended frequency of 4 hourly, 20 tablets dispensed) or the ‘reduced’ group (received half the amount of oxycodone, taken half as frequently) at hospital discharge. Primary outcomes were screening to recruitment rate, percentage completing follow-ups, and acceptability of the trial procedures. Acceptability was measured quantitatively at weeks 1 and 2 post-discharge and qualitatively by interview at 6 weeks post-discharge. Adverse events were collected up to 6-weeks post-discharge.

Results

In four months, we screened 254 people, of which 72 were eligible and 53 were recruited (recruitment rate = 21%). 93% participants completed all their follow up surveys. Participants scored the trial intervention between neutral and acceptable (3.6/5 for both groups and weeks). 39 interviews were conducted where both clinicians and patients reported strong support for the pilot trial design. Few adverse events occurred across both groups, the most common being constipation.

Conclusions

This pilot trial indicated that a full-scale trial would be feasible and acceptable. Such a trial could provide evidence of comparative effectiveness for the reduced opioid regimen in this population.

Trial registration

The trial was pre-registered in Australian New Zealand Clinical Trials Registry (ACTRN12623001070628).